Jefferies Financial Group Inc. Takes $3.42 Million Position in Sarepta Therapeutics, Inc. $SRPT

Jefferies Financial Group Inc. bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 190,200 shares of the biotechnology company’s stock, valued at approximately $3,418,000. Jefferies Financial Group Inc. owned about 0.18% of Sarepta Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. iSAM Funds UK Ltd acquired a new stake in shares of Sarepta Therapeutics in the third quarter worth $25,000. Kestra Advisory Services LLC bought a new position in Sarepta Therapeutics in the 4th quarter worth $25,000. Meeder Asset Management Inc. bought a new position in Sarepta Therapeutics in the 2nd quarter worth $27,000. Ancora Advisors LLC lifted its position in Sarepta Therapeutics by 200.0% during the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Down 3.4%

Sarepta Therapeutics stock opened at $20.86 on Friday. Sarepta Therapeutics, Inc. has a 12 month low of $14.68 and a 12 month high of $25.32. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -7.19, a price-to-earnings-growth ratio of 0.32 and a beta of 0.23. The business has a 50 day moving average price of $17.73 and a two-hundred day moving average price of $18.32. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The firm had revenue of $401.25 million during the quarter, compared to analysts’ expectations of $366.39 million. During the same period last year, the business earned $2.02 earnings per share. Sarepta Therapeutics’s quarterly revenue was down 34.3% compared to the same quarter last year. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 3.43 EPS for the current year.

Analyst Ratings Changes

SRPT has been the topic of a number of recent analyst reports. Piper Sandler dropped their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Thursday, July 9th. Weiss Ratings lowered Sarepta Therapeutics from a “sell (d)” rating to a “sell (e+)” rating in a report on Wednesday, August 19th. Wall Street Zen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research raised Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Wolfe Research upgraded shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday, July 9th. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.06.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.